很少有研究探讨芳香酶抑制剂治疗与工作年龄乳腺癌幸存者角色功能的关系。我们的研究旨在确定治疗前的社会人口统计学和健康/治疗相关特征以及每六个月测量一次的患者报告的症状如何影响早期乳腺癌人工智能治疗 18 个月期间的角色功能。使用线性混合效应模型对纵向研究数据进行二次分析，以检查通过医疗结果研究简表 36 v2 测量的角色身体 (RP) 和角色情绪 (RE) 功能。绝经后妇女样本 (N = 351) 由三个队列组成：化疗后阿那曲唑 (CFAI)、仅阿那曲唑（仅 AI）和非癌症对照。我们对变量的选择和对结果的解释理论上是基于癌症生存和工作模型。逐步向后删除决定了最终模型中包含哪些预测因子，考虑到治疗组。与对照组相比，两个治疗组的 RP 功能都受到更大的限制。与仅使用 AI 相比，CFAI 对 RP 的影响是其两倍。虽然 RP 模型显示了社会人口统计学、健康/治疗和症状特征的重要预测因子，但只有症状与 RE 功能的更大限制相关。结果在 p< .05 时显着。从急性生存期过渡到延长生存期是一个关键时刻，其中多种因素使乳腺癌幸存者面临角色功能减弱的风险。在全身治疗期间解决角色功能限制的早期干预措施可能会带来更好的工作结果并提高长期生存的质量。© 2024。作者获得 Springer Science Business Media, LLC（Springer Nature 旗下公司）的独家许可。

Few studies have examined aromatase inhibitor therapy relating to role function in breast cancer survivors of working age. Our study sought to identify how pre-therapy sociodemographic and health/treatment-related characteristics, as well as patient-reported symptoms measured every six-months, influence role function during 18 months of AI therapy for early-stage breast cancer.We performed a secondary analysis of longitudinal study data using linear mixed-effects modeling to examine role physical (RP) and role emotional (RE) functioning measured with the Medical Outcome Study Short Form 36 v2. The sample of postmenopausal women (N = 351) consisted of three cohorts: chemotherapy followed by anastrozole (CFAI), anastrozole only (AI only), and non-cancer controls. Our choice of variables and interpretation of findings was theoretically based on the Cancer Survivorship and Work Model. Stepwise backward deletion determined which predictors to include in the final model, accounting for treatment group.Both treatment groups were associated with greater limitations in RP functioning than controls. CFAI had twice the impact on RP compared to AI only. While the RP model displayed significant predictors across sociodemographic, health/treatment, and symptom characteristics, only symptoms were associated with greater limitations in RE functioning. Findings were significant at p < .05.Transitioning from acute to extended survivorship is a critical juncture in which multiple factors place breast cancer survivors at risk of diminished role function.Early interventions to address role function limitations during systemic treatment may lead to better work outcomes and improve the quality of long-term survivorship.© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.